Relugolix: all 42 studies that test it

Page 1 of 1. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.

• Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CTRecruitingNCT07455903Phase 2
• Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA TrialRecruitingNCT07025369Phase 2
• Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine FibroidsRecruitingNCT06671548Phase 3
• REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac TrialRecruitingNCT06650579Phase 3
• Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate CancerRecruitingNCT06631521Phase 1
• Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL TrialRecruitingNCT06499870Phase 2
• The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled TrialRecruitingNCT06439524Phase 3
• Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate CancerRecruitingNCT06330805Phase 2
• Relugolix + Enzalutamide Study in High-Risk Prostate CancerRecruitingNCT06130995Phase 1
• Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate CancerNot yet recruitingNCT06129851Phase 2
• The SUGAR Study; SBRT and Relugolix) for Prostate CancerRecruitingNCT06111781Phase 2
• A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or EndometriosisRecruitingNCT05862272Phase 3
• RecoverPC: Relugolix vs GnRH Agonist in Quality of LifeRecruitingNCT05765500Phase 2
• Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide AcetateCompletedNCT05605964Phase 3Results posted
• RElugolix VErsus LeUprolide Cardiac TrialActive, not recruitingNCT05320406Phase 2Results posted
• Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine FibroidsCompletedNCT03751124Phase 3Results posted
• SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated PainCompletedNCT03654274Phase 3Results posted
• LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine FibroidsCompletedNCT03412890Phase 3Results posted
• LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine FibroidsCompletedNCT03103087Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate CancerCompletedNCT03085095Phase 3Results posted
• LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine FibroidsCompletedNCT03049735Phase 3Results posted
• A Food Effect Study of TAK-385 Final FormulationCompletedNCT02792062Phase 1Results posted
• A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine FibroidsCompletedNCT02655237Phase 3Results posted
• A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine FibroidsCompletedNCT02655224Phase 3Results posted
• Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy ParticipantsCompletedNCT02396147Phase 1Results posted
• TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability StudyCompletedNCT02252354Phase 1Results posted
• A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate CancerCompletedNCT02141659Phase 1Results posted
• Safety and Efficacy of TAK-385 for Patients With Localized Prostate CancerCompletedNCT02135445Phase 2Results posted
• A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy SubjectsCompletedNCT02093390Phase 1Results posted
• A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate CancerCompletedNCT02083185Phase 2Results posted
• Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy StagingCompletedNCT07069465Early Phase 1
• Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)Active, not recruitingNCT06463457Phase 2
• Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy TreatmentWithdrawnNCT06279195Phase 2
• Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean StudyActive, not recruitingNCT05053152Phase 2
• Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialActive, not recruitingNCT05050084Phase 3
• A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult MenCompletedNCT04714554Phase 1
• Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With EndometriosisCompletedNCT03931915Phase 3
• SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated PainCompletedNCT03204331Phase 3
• SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated PainCompletedNCT03204318Phase 3
• Efficacy and Safety of TAK-385 in the Treatment of EndometriosisCompletedNCT01458301Phase 2
• A Long-term Extension Study of TAK-385 in the Treatment of EndometriosisCompletedNCT01452685Phase 2
• Efficacy and Safety of TAK-385 in the Treatment of Uterine FibroidsCompletedNCT01452659Phase 2

← Relugolix overview